Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Rhythm Pharmaceuticals, Inc. RYTM G&A

Discontinued — last reported Q3 '17

G&A at other companies

Praxis Precision Medicines, Inc.PRAX

$27.87M+100%

Protagonist TherapeuticsPTGX

——

Apogee Therapeutics, Inc.APGE

——

Segments

By segment

See full

Single reportable segment$7.89M-1.2%

Other financials

Income statement

See full

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

See full

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

See full

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

See full

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

See full

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

See full

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed November 14, 2017, on SEC EDGAR. View the filing →

Questions, answered.

What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.